BioMarin Pharmaceutical

E917097

BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.

Try in SPARQL Jump to: Statements Referenced by

Statements (48)

Predicate Object
instanceOf biotechnology company
public company
businessModel commercialization of rare disease therapies
research and development of enzyme replacement therapies
coDeveloped Aldurazyme NERFINISHED
coDevelopedWith Genzyme NERFINISHED
country United States of America
surface form: United States
developsTreatmentFor CLN2 disease
achondroplasia
mucopolysaccharidosis I
mucopolysaccharidosis IVA NERFINISHED
mucopolysaccharidosis VI
phenylketonuria
focusesOn orphan drugs
foundedBy Alejandro Zaffaroni NERFINISHED
Christopher Starr NERFINISHED
Grant W. Denison Jr. NERFINISHED
hasAbbreviation BioMarin NERFINISHED
hasCollaboration Genzyme NERFINISHED
hasOfficialWebsite https://www.biomarin.com/
hasProduct Aldurazyme NERFINISHED
Brineura NERFINISHED
Kuvan NERFINISHED
Naglazyme NERFINISHED
Palynziq NERFINISHED
Vimizim NERFINISHED
Voxzogo NERFINISHED
hasResearchFocus enzyme replacement therapy
gene therapy
hasTherapeuticArea lysosomal storage disorders
metabolic disorders
neurological rare diseases
skeletal dysplasias
headquartersLocation San Rafael, California NERFINISHED
inception 1997
industry biotechnology
pharmaceuticals
languageOfWorkOrName English
legalForm corporation
listedIn NASDAQ Biotechnology Index NERFINISHED
operatesIn Asia
Europe
North America
regulatoryFocus orphan drug designation
specializesIn therapies for rare genetic diseases
stockExchange NASDAQ
targetMarket patients with rare genetic disorders
tickerSymbol BMRN NERFINISHED

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Novato, California, United States hasEmployer BioMarin Pharmaceutical
subject surface form: Novato, California